Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Axsome Therapeutics, Inc. (NASDAQ:AXSM) has been assigned an average rating of “Moderate Buy” from the nineteen research firms that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and seventeen have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $214.1765.

Several brokerages have recently commented on AXSM. Cantor Fitzgerald reiterated an “overweight” rating on shares of Axsome Therapeutics in a research note on Wednesday, January 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $225.00 price target on shares of Axsome Therapeutics in a report on Monday. TD Cowen reiterated a “buy” rating on shares of Axsome Therapeutics in a report on Monday. HC Wainwright increased their price objective on shares of Axsome Therapeutics from $200.00 to $260.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Finally, Wolfe Research started coverage on shares of Axsome Therapeutics in a research note on Monday. They set an “outperform” rating and a $230.00 target price for the company.

Key Stories Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Q4 results beat Street estimates — Axsome reported EPS that topped consensus and reported quarterly revenue of $196M, above estimates, and 2025 full‑year revenue grew ~66% to $638.5M, driven by Auvelity and Sunosi. MSN Article
• Positive Sentiment: Analyst support: Needham reaffirmed a Buy and set a $225 price target (~28–29% upside from current levels), which can support share demand. Benzinga Note
• Neutral Sentiment: Company filed a full press release, slide deck and held the earnings call — useful for investors looking for forward guidance, commercialization detail and upcoming catalysts. Business Insider Release
• Neutral Sentiment: Earnings call and transcript are available for deeper read — helpful to assess management’s color on demand trends for Auvelity/Sunosi and development timelines. Yahoo Finance Call Summary Call Transcript
• Negative Sentiment: Valuation and pipeline concerns: a Seeking Alpha review downgraded AXSM to Hold, arguing the pipeline may be overvalued and commercial upside for key assets is uncertain — a factor that can pressure the stock despite top‑line beats. Seeking Alpha
• Negative Sentiment: Company remains loss‑making with negative margins and high leverage metrics noted in filings — investors watching profitability and cash flow may be cautious. Zacks Metrics

Insider Activity at Axsome Therapeutics

In other news, insider Ari Maizel sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $184.44, for a total transaction of $1,383,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Nick Pizzie sold 12,000 shares of the stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $187.92, for a total value of $2,255,040.00. Following the transaction, the chief financial officer owned 42,588 shares in the company, valued at approximately $8,003,136.96. This trade represents a 21.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 308,874 shares of company stock valued at $51,390,805. 22.40% of the stock is currently owned by insiders.

Institutional Trading of Axsome Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Stanley Laman Group Ltd. acquired a new stake in shares of Axsome Therapeutics during the third quarter valued at about $2,125,000. Aberdeen Group plc boosted its position in Axsome Therapeutics by 15.5% during the 3rd quarter. Aberdeen Group plc now owns 94,648 shares of the company’s stock worth $11,495,000 after buying an additional 12,732 shares during the period. Swiss National Bank grew its holdings in Axsome Therapeutics by 6.9% during the 2nd quarter. Swiss National Bank now owns 65,200 shares of the company’s stock worth $6,806,000 after acquiring an additional 4,200 shares during the last quarter. Bank of New York Mellon Corp increased its position in Axsome Therapeutics by 55.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 203,632 shares of the company’s stock valued at $21,257,000 after acquiring an additional 72,609 shares during the period. Finally, Cabot Wealth Management Inc. acquired a new position in Axsome Therapeutics in the 3rd quarter valued at approximately $675,000. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Stock Down 4.9%

Axsome Therapeutics stock opened at $174.76 on Thursday. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.50. The company’s 50-day moving average is $174.45 and its 200-day moving average is $144.94. The firm has a market capitalization of $8.81 billion, a PE ratio of -37.42, a P/E/G ratio of 13.22 and a beta of 0.40. Axsome Therapeutics has a fifty-two week low of $86.99 and a fifty-two week high of $191.50.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Monday, February 23rd. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.14. The business had revenue of $196.00 million during the quarter, compared to the consensus estimate of $191.33 million. Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The firm’s revenue for the quarter was up 65.0% compared to the same quarter last year. Sell-side analysts anticipate that Axsome Therapeutics will post -2.79 earnings per share for the current year.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.